PureTech Health PLC Notice of Results (3409Z)
March 14 2017 - 3:01AM
UK Regulatory
TIDMPRTC
RNS Number : 3409Z
PureTech Health PLC
14 March 2017
14 March 2017
PureTech Health plc
Notice of Results
PureTech Health plc ("PureTech", LSE: PRTC), a
cross-disciplinary biopharmaceutical company, plans to announce its
financial results for the year ended 31 December 2016 on Thursday 6
April 2017.
As previously announced PureTech will also hold its annual
Capital Markets Meeting in London on Tuesday 9 May 2017 from
13.00-17.00 BST. The meeting will feature PureTech presenters
including members of the Company's Board of Directors, senior team,
key scientific advisors, and management from the Company's
programs. Please confirm if you would like to attend the Capital
Markets Meeting to PureTech.Event@fticonsulting.com
About PureTech Health
PureTech Health (PureTech Health plc, PRTC.L) is a
cross-disciplinary biopharmaceutical company creating 21(st)
century medicines that modulate the adaptive human systems. Our
therapies target the immune, nervous, and gastro-intestinal systems
by addressing the underlying pathophysiology of disease from a
systems perspective rather than through a single receptor or
pathway. We have multiple human proof-of-concept studies and
pivotal or registration studies expected to read out in the
near-term. PureTech Health's rich and growing research and
development pipeline has been developed in collaboration with some
of the world's leading scientific experts who, along with
PureTech's experienced team and board, analyse more than 650
scientific discoveries per year to identify and advance only the
opportunities we believe hold the most promise for patients. This
team and process place PureTech Health on the cutting edge of
ground-breaking science and technological innovation and leads the
Company between and beyond existing disciplines. For more
information, visit www.puretechhealth.com or connect with us on
Twitter.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
For further information:
PureTech Health FTI Consulting
Allison Mead Ben Atwell, Matthew
+1 617 651 3156 Cole
amead@puretechhealth.com +44 (0) 20 3727
1000
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORDBGDXUXBBGRX
(END) Dow Jones Newswires
March 14, 2017 03:01 ET (07:01 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024